Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer.

[1]  M. Picchio,et al.  Pretreatment 18F-FAZA PET Predicts Success of Hypoxia-Directed Radiochemotherapy Using Tirapazamine , 2007, Journal of Nuclear Medicine.

[2]  Daniela Thorwarth,et al.  Hypoxia dose painting by numbers: a planning study. , 2007, International journal of radiation oncology, biology, physics.

[3]  M. Picchio,et al.  Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  M. Schwaiger,et al.  Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  W. Oyen,et al.  Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  D. Mankoff,et al.  Hypoxia imaging-directed radiation treatment planning , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  R. Fisher,et al.  Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B J Krause,et al.  PET and PET/CT studies of tumor tissue oxygenation. , 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[9]  J. Bussink,et al.  Dynamics of Hypoxia, Proliferation and Apoptosis after Irradiation in a Murine Tumor Model , 2006, Radiation research.

[10]  Daniela Thorwarth,et al.  Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer , 2005, BMC Cancer.

[11]  D. Brizel,et al.  Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  B. Solomon,et al.  Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging , 2005, Molecular Cancer Therapeutics.

[13]  Lester J. Peters,et al.  Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Branislav Jeremic,et al.  Positron Emission Tomography for Radiation Treatment Planning , 2005, Strahlentherapie und Onkologie.

[15]  J. Bussink,et al.  Hypoxic cell turnover in different solid tumor lines. , 2005, International journal of radiation oncology, biology, physics.

[16]  Søren M Bentzen,et al.  Theragnostic imaging for radiation oncology: dose-painting by numbers. , 2005, The Lancet. Oncology.

[17]  Matthias Reimold,et al.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  David J. Yang,et al.  Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma , 1996, European Journal of Nuclear Medicine.

[19]  Morand Piert,et al.  Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  Radhe Mohan,et al.  Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results. , 2004, International journal of radiation oncology, biology, physics.

[21]  M. Eble,et al.  pO2 Polarography Versus Positron Emission Tomography ([18F] Fluoromisonidazole, [18F]-2-Fluoro-2’-Deoxyglucose) , 2004, Strahlentherapie und Onkologie.

[22]  Peter Vaupel,et al.  Tumor microenvironmental physiology and its implications for radiation oncology. , 2004, Seminars in radiation oncology.

[23]  F. O’Sullivan,et al.  Hypoxia and Glucose Metabolism in Malignant Tumors , 2004, Clinical Cancer Research.

[24]  H. Herzog,et al.  NEMA NU2-2001 guided performance evaluation of four Siemens ECAT PET scanners , 2003, IEEE Transactions on Nuclear Science.

[25]  Michael Molls,et al.  Tumor Volume and Tumor Hypoxia in Head and Neck Cancers , 2003, Strahlentherapie und Onkologie.

[26]  Peter Kneschaurek,et al.  Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience. , 2003, International journal of radiation oncology, biology, physics.

[27]  O. S. Nielsen,et al.  Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  Michael J. Welch,et al.  In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  Mark A Mintun,et al.  Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. , 2003, International journal of radiation oncology, biology, physics.

[30]  M Alber,et al.  On biologically conformal boost dose optimization. , 2003, Physics in medicine and biology.

[31]  V. Oikonen,et al.  Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  S Mutic,et al.  A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[33]  R. Fisher,et al.  Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Piert,et al.  Dependency of the [18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. , 2000, Nuclear medicine and biology.

[35]  C C Ling,et al.  Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. , 2000, International journal of radiation oncology, biology, physics.

[36]  M. Dewhirst,et al.  Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  M Molls,et al.  Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. , 1999, International journal of radiation oncology, biology, physics.

[38]  M. Piert,et al.  Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia , 1999, European Journal of Nuclear Medicine.

[39]  H. Machulla,et al.  Fluoroazomycin arabinoside (FAZA): synthesis, 2H and 3H‐labelling and preliminary biological evaluation of a novel 2‐nitroimidazole marker of tissue hypoxia , 1999 .

[40]  J Beier,et al.  MRI-assisted specification/localization of target volumes. Aspects of quality control. , 1998, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[41]  G Brix,et al.  Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[43]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[44]  T K Lewellen,et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.

[45]  M. Parliament,et al.  Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside. , 1996, The British journal of cancer. Supplement.

[46]  K. Krohn,et al.  Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  K L Lindsley,et al.  Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. , 1995, International journal of radiation oncology, biology, physics.

[48]  T W Griffin,et al.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. , 1992, International journal of radiation oncology, biology, physics.

[49]  J. D. Chapman,et al.  Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  E. Hall,et al.  Radiobiology for the radiologist , 1973 .